Nov 2 (Reuters) - CSL Ltd CSL.AX :
* ORPHAN DRUG DESIGNATION GRANTED FOR CSL BEHRING'S INVESTIGATIONAL PLASMA-DERIVED HEMOPEXIN THERAPY FOR SICKLE CELL DISEASE
* CSL BEHRING - PHASE 1 CLINICAL DEVELOPMENT UNDERWAY FOR CSL889
Nov 2 (Reuters) - CSL Ltd CSL.AX :
* ORPHAN DRUG DESIGNATION GRANTED FOR CSL BEHRING'S INVESTIGATIONAL PLASMA-DERIVED HEMOPEXIN THERAPY FOR SICKLE CELL DISEASE
* CSL BEHRING - PHASE 1 CLINICAL DEVELOPMENT UNDERWAY FOR CSL889